comprehensive -WSS

comprehensive

author：fashion 2025-10-03 19:57:25 - browse：6947

A sign of Lilly on the top of its biotechnology center — coverage from STAT — Adobe

Eli Lilly reported Thursday that its experimental weekly insulin worked as well as daily basal insulin products in two late-stage studies, paving the way for the drug to compete with a similar weekly insulin developed by Novo Nordisk.

In a 52-week trial of type 2 diabetes patients using insulin for the first time, those on the weekly insulin, called efsitora alfa, had a 1.34% reduction in blood sugar levels, while people on the comparator daily insulin degludec, sold as Tresiba by Novo, had a 1.26% lowering. That resulted in patients having blood sugar levels, known as A1C readings, of 6.87% and 6.95%, respectively.

In a separate 26-week trial of type 2 patients who have been using insulin, those on efsitora and the comparator daily insulin glargine, sold by Lilly as Basaglar and Sanofi as Lantus, both saw A1C reductions of 1.07%, resulting in blood sugar levels of 7.12% and 7.11%, respectively.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： BioMarin wins approval for gene therapy to treat hemophilia A
Next article： CDC advisory panel says seniors 'may' get RSV vaccine

leisure time

WSS

Flagship, Pfizer team up in deal worth up to $7 billion

15 die by electrocution after transformer explodes in northern India

What AAP's gender

Feds fine Medicare Advantage plans for overcharging members

BridgeBio heart drug succeeds in pivotal study

Idaho college killings: Prosecutors dispute DNA could have been planted at murder scene

hotspot

comprehensive

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

focus

Novavax promises a turnaround & Lilly roils the obesity market

Johnson & Johnson sues to stop Medicare negotiation

Drug repurposing or repositioning? The language matters

Psilocybin's anti

In Memoriam: Notable people who died in 2023

What we know about the American soldier detained in North Korea

Anesthesiologist group: stop taking Ozempic before surgery

Idaho college killings: Prosecutors dispute DNA could have been planted at murder scene

The cancer drug shortage isn’t new — and neither are the solutions

Diversity in medical illustrations gets boost from Chidiebere Ibe

leisure time

Robert Kennedy Jr.'s presidential campaign attracts GOP

Why you get paid to donate plasma but not blood

Robert Kennedy Jr.'s presidential campaign attracts GOP

Psilocybin's anti

Flagship, Pfizer team up in deal worth up to $7 billion

Vivek Ramaswamy, who's embraced Trump on the campaign trail, condemned him after Jan. 6

hotspot

focus

leisure time

hotspot